Form: 10KSB40

Annual Report Form for Small Businesses that also have a Positive Response to Item 405

April 15, 1998

EXHIBIT 11

Published on April 15, 1998



EXHIBIT 11


CYTOCLONAL PHARMACEUTICS INC.
COMPUTATION OF NET (LOSS) PER COMMON SHARE


Year Ended December 31,
------------------------------
1996 1997
------------ ------------

Net (loss) ($2,890,000) ($3,252,000)

Add cumulative preferred dividend (307,000) (234,000)
------------ ------------

NET (LOSS) USED FOR COMPUTATION ($3,197,000) ($3,486,000)
------------ ------------
------------ ------------

Weighted average number of common shares
outstanding 7,640,000 8,268,000
------------ ------------
------------ ------------

Net (loss) per common share ($0.42) ($0.42)
------------ ------------
------------ ------------





11